The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days.
The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.
The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sales of MannKind's inhaled insulin Afrezza totaled €1 million in the first quarter of its commercial launch.
Sanofi reports first-quarter earnings on Thursday morning, but it's unclear if sales of the recently launched inhaled insulin medication Afrezza will be disclosed.
Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.
Will the FDA bring together DMD experts for a single meeting to review both BioMarin's drisapersen and Sarepta's eteplirsen, or will two separate meetings be scheduled?
Overall, Bristol sales in the March quarter were $4 billion, a 6% increase from one year ago and higher than consensus.
On an adjusted basis, Merck reported first quarter earnings per share of 85 cents, topping the Street consensus of 74 cents per share.